Valuation: Nipro Corporation

Market Cap 275B 1.72B 1.5B 1.39B 1.28B 2.41B 165B 2.46B 16.46B 6.44B 81.71B 6.47B 6.33B P/E 2027 *
18x
P/E 2028 * 13.9x
Enterprise Value 784B 4.92B 4.27B 3.97B 3.66B 6.89B 469B 7.01B 46.95B 18.38B 233B 18.46B 18.06B EV / Sales 2027 *
1.12x
EV / Sales 2028 * 1.05x
Free-Float
87.38%
Yield 2027 *
2.17%
Yield 2028 * 2.72%
Jul. 30 Nipro Corporation Receives Fda 510(K) Clearance for Elisio-Hx Dialyzer and Introduces Hds to the United States CI
Jul. 28 Vat Holding AG signed a letter of intent to acquire an unknown minority stake in Atonarp Inc. from Nipro Corporation. CI
Jul. 14 Jefferies Adjusts Nipro's Price Target to 1,700 Yen From 1,500 Yen, Keeps at Hold MT
May. 12 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
May. 12 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
May. 01 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
Mar. 11 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
Feb. 08 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
Dec. 24 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
Nov. 10 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
25-06-10 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
25-06-09 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
25-05-13 Jefferies Adjusts Nipro's Price Target to 1,300 Yen from 1,400 Yen, Keeps at Hold MT
1 day-2.78%
1 week+3.50%
Current month+3.08%
1 month+5.93%
3 months+9.02%
6 months+14.84%
Current year+10.02%
1 week 1,579.5
Extreme 1579.5
1,678
1 month 1,536.5
Extreme 1536.5
1,678
Current year 1,401
Extreme 1401
1,760.5
1 year 1,367.5
Extreme 1367.5
1,760.5
3 years 1,015.5
Extreme 1015.5
1,760.5
5 years 987
Extreme 987
1,760.5
10 years 908
Extreme 908
1,760.5
Manager TitleAgeSince
Director of Finance/CFO 57 2025-05-31
President 58 2025-05-31
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 81 2025-06-25
Director/Board Member 53 2009-05-31
Director/Board Member 58 2009-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.78%+3.50%+16.86%+57.38% 1.72B
-2.21%+4.82%-17.85%-6.32% 183B
-2.09%+4.51%-6.47%-2.88% 110B
-2.00%+2.35%+7.00%+67.36% 60.75B
+3.50%+0.47%+28.65%+49.27% 50.01B
-1.75%+8.16%-8.86%-40.98% 45.59B
-2.40%+3.96% - - 33.08B
-0.80%+5.76%-16.30%-43.69% 28.76B
+0.63%-4.47%+36.27%-7.08% 23.9B
-1.54%+9.77%+0.85%+0.51% 22.53B
Average -1.14%+4.42%+4.46%+8.18% 55.88B
Weighted average by Cap. -1.41%+5.48%-3.94%+3.62%

Financials

2027 *2028 *
Net sales 701B 4.39B 3.82B 3.54B 3.27B 6.16B 420B 6.27B 41.96B 16.43B 208B 16.5B 16.14B 729B 4.57B 3.97B 3.69B 3.4B 6.41B 436B 6.52B 43.65B 17.09B 217B 17.17B 16.79B
Net income 15.39B 96.54M 83.85M 77.87M 71.81M 135M 9.22B 138M 922M 361M 4.58B 363M 355M 19.95B 125M 109M 101M 93.09M 175M 11.95B 179M 1.19B 468M 5.93B 470M 460M
Net Debt 509B 3.19B 2.77B 2.58B 2.38B 4.47B 305B 4.56B 30.49B 11.94B 151B 11.99B 11.73B 489B 3.07B 2.67B 2.48B 2.28B 4.3B 293B 4.38B 29.31B 11.47B 146B 11.52B 11.27B
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
38,593
Date Price Change Volume
26-07-31 ¥1,625.00 -2.78% 635,600
26-07-30 ¥1,671.50 +0.15% 677,700
26-07-29 ¥1,669.00 +2.58% 872,800
26-07-28 ¥1,627.00 -0.06% 568,400
26-07-27 ¥1,628.00 +3.69% 912,700
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,671.50JPY
Average target price
1,986.00JPY
Spread / Average Target
+18.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 8086 Stock